Eugene Bleecker
Pulmonary Disease · Winston Salem, NCNPI 1811971104
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $255,224 of the $356,638 with a category attached, or 71.6%. It is spread thinly across 14 manufacturers, the largest accounting for just 23.7%. Reporting peaked in 2019 at $217,320 and has fallen 99.8% since, to $375 in 2025. Among pulmonary disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $1739.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$85K
- Sanofi$59K
- Regeneron Healthcare Solutions, Inc.$56K
- GSK$46K
- AstraZeneca$39K
- Alk-abello, Inc$17K
- plus $55K from 8 others
Across 25 payments — averaging $15,451 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$281K
- Vertex$41K
- Teva Pharmaceuticals USA, Inc.$32K
- Sanofi US Services Inc.$28K
- Novartis$4K
What the payments were for
- Consulting fees$255,22472%
- Speaking & faculty fees$27,6358%
- Travel & lodging$69,99020%
- Food & beverage$3,7711%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 64 | $84,564 |
| Sanofi | 19 | $59,444 |
| Regeneron Healthcare Solutions, Inc. | 27 | $55,525 |
| GSK | 35 | $46,289 |
| AstraZeneca | 41 | $38,879 |
| Alk-abello, Inc | 3 | $16,706 |
| Regeneron | 1 | $13,300 |
| Astrazeneca AB | 2 | $8,861 |
| Novartis Pharma AG | 1 | $8,368 |
| Sanofi-aventis U.S. LLC | 4 | $7,991 |
| Novartis | 4 | $7,363 |
| Boehringer Ingelheim International GmbH | 2 | $3,538 |
| Boehringer Ingelheim | 1 | $3,384 |
| Chiesi USA, Inc. | 1 | $2,425 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$126,898
- FASENRA$26,122
- Odactra$16,706
- NUCALA$13,645
- IGE025A_XOLAIR _RESPIRATORY$8,368
- SPIRIVA RESPIMAT$6,923
- AIRSUPRA$2,377
How this compares
$356,638 in reported general payments places this provider in the 95th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Winston Salem
- Jill OharWinston Salem$226K
- Stephen PetersWinston Salem$59K
- Jessica FieldWinston Salem$55K
- Wendy MooreWinston Salem$48K
- Christina BellingerWinston Salem$32K
- Kapilkumar PatelWinston Salem$21K
- Chad MarionWinston Salem$17K
- Andrew NamenWinston Salem$16K
- Victor OrtegaWinston Salem$15K
- Michael PritchettPinehurst$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.